Jula Inrig

CIK: 0001902368

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)23 (67.6%)

Position reduction

Option Exercises (M)5 (14.7%)

Derivative conversions

Awards (A)5 (14.7%)

Compensation grants

Other (G, F, J, C, D, …)1 (2.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TVTX

Travere Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (34 total)

TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
25.4K shares at avg. $62.02$1.6M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
400 shares at avg. $65.31$26K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
1.6K shares at avg. $63.69$102K
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Sale(S)
Direct
17.3K shares at avg. $62.62$1.1M
TVTX
Travere Therapeutics, Inc.
Sep 15, 2026
Exercise(M)
Direct
32.4K shares at avg. $8.93$289K
TVTX
Travere Therapeutics, Inc.
Jun 22, 2026
Gift(G)
Direct
468 shares-
TVTX
Travere Therapeutics, Inc.
May 6, 2026
Sale(S)
Direct
311 shares at avg. $43.95$14K
TVTX
Travere Therapeutics, Inc.
May 5, 2026
Sale(S)
Direct
2.2K shares at avg. $46.65$101K
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Award(A)
Performance-based restricted stock units
Direct
8.5K shares-
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Exercise(M)
Direct
4.3K shares-
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Exercise(M)
Direct
20K shares at avg. $22.40$448K
TVTX
Travere Therapeutics, Inc.
May 4, 2026
Sale(S)
Direct
20K shares at avg. $45.00$900K
TVTX
Travere Therapeutics, Inc.
Apr 15, 2026
Sale(S)
Direct
1K shares at avg. $42.61$43K
TVTX
Travere Therapeutics, Inc.
Apr 14, 2026
Sale(S)
Direct
7.2K shares at avg. $41.93$303K
TVTX
Travere Therapeutics, Inc.
Apr 13, 2026
Award(A)
Direct
14K shares-
TVTX
Travere Therapeutics, Inc.
Feb 4, 2026
Sale(S)
Direct
232 shares at avg. $32.85$8K
TVTX
Travere Therapeutics, Inc.
Feb 4, 2026
Sale(S)
Direct
1.5K shares at avg. $32.11$50K
TVTX
Travere Therapeutics, Inc.
Feb 3, 2026
Sale(S)
Direct
7K shares at avg. $32.12$223K
TVTX
Travere Therapeutics, Inc.
Jan 31, 2026
Award(A)
Direct
28.1K shares-
TVTX
Travere Therapeutics, Inc.
Jan 6, 2026
Sale(S)
Direct
445 shares at avg. $37.75$17K
TVTX
Travere Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
2K shares at avg. $40.18$82K
TVTX
Travere Therapeutics, Inc.
Dec 24, 2025
Sale(S)
Direct
15K shares at avg. $42.00$630K
TVTX
Travere Therapeutics, Inc.
Dec 24, 2025
Exercise(M)
Direct
15K shares at avg. $8.93$134K
TVTX
Travere Therapeutics, Inc.
Jul 1, 2025
Sale(S)
Direct
815 shares at avg. $14.65$12K
TVTX
Travere Therapeutics, Inc.
Feb 12, 2025
Sale(S)
Direct
2.6K shares at avg. $23.53$60K

		Type	Shares	Price		Ownership
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	25,390	$62.02	$1,574,604	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	400	$65.31	$26,124	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,600	$63.69	$101,896	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	17,284	$62.62	$1,082,397	Direct
Sep 15, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	32,395	$8.93	$289,287	Direct
Jun 22, 2026	TVTX Travere Therapeutics, Inc.	Gift(G)	468	-	$0	Direct
May 6, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	311	$43.95	$13,668	Direct
May 5, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	2,174	$46.65	$101,417	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Award(A) Performance-based restricted stock units	8,500	-	-	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	4,250	-	$0	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Exercise(M)	20,000	$22.40	$448,000	Direct
May 4, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	20,000	$45.00	$900,000	Direct
Apr 15, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,018	$42.61	$43,377	Direct
Apr 14, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	7,215	$41.93	$302,516	Direct
Apr 13, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	14,000	-	$0	Direct
Feb 4, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	232	$32.85	$7,621	Direct
Feb 4, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	1,547	$32.11	$49,674	Direct
Feb 3, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	6,956	$32.12	$223,427	Direct
Jan 31, 2026	TVTX Travere Therapeutics, Inc.	Award(A)	28,130	-	$0	Direct
Jan 6, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	445	$37.75	$16,799	Direct
Jan 5, 2026	TVTX Travere Therapeutics, Inc.	Sale(S)	2,031	$40.18	$81,606	Direct
Dec 24, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	15,000	$42.00	$630,005	Direct
Dec 24, 2025	TVTX Travere Therapeutics, Inc.	Exercise(M)	15,000	$8.93	$133,950	Direct
Jul 1, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	815	$14.65	$11,940	Direct
Feb 12, 2025	TVTX Travere Therapeutics, Inc.	Sale(S)	2,568	$23.53	$60,426	Direct

1-25 of 34 transactions

About Inrig Jula

Inrig Jula (SEC CIK 0001902368) files insider reports with the SEC as EVP, Head of R&D & CMO of Travere Therapeutics, Inc. (TVTX).

Signal8 holds 14 ownership filings by Inrig Jula, all Form 4s, filed between Sep 9, 2024 and Sep 17, 2026. Those filings report 34 transactions, from Sep 5, 2024 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Inrig Jula's filings is in SAN DIEGO, CA.

Recent filings by Inrig Jula

Sep 15, 2026: Open-market sales of TVTX shares (4 lines, Form 4, code S).
Sep 15, 2026: Option exercise of TVTX shares (Form 4, code M).
Jun 22, 2026: Gift of TVTX shares (Form 4, code G).
May 6, 2026: Open-market sale of TVTX shares (Form 4, code S).
May 5, 2026: Open-market sale of TVTX shares (Form 4, code S).

Other insiders filing for Travere Therapeutics, Inc. (TVTX)

Dube Eric M, CHIEF EXECUTIVE OFFICER
ROTE WILLIAM E., Chief Research Officer
Heerma Peter, EVP, CHIEF COMMERCIAL OFFICER
REED ELIZABETH E, Chief Legal Officer and GC
Cline Christopher R., CHIEF FINANCIAL OFFICER
Calvin Sandra, SVP, CHIEF ACCOUNTING OFFICER

How to read Form 4 transaction codes